Comparison of diabetes phenotype in children and their mothers with permanent neonatal diabetes mellitus carrying the same KCNJ11 variants

Bowman P, Sulen A, Barbetti F, et al. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. Lancet Diabetes Endocrinol 6, 637–646, 2018.Search in Google Scholar

Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 13, 59, 2013.10.1186/1471-2431-13-59363747723601190Search in Google Scholar

Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life with the phenotype determined by genotype. Diabetologia 49, 1190–1197, 2006.10.1007/s00125-006-0246-z16609879Search in Google Scholar

Kobzova J, Vignerova J, Blaha P, Krejcovsky L, Riedlova J. The 6th nationwide anthropological survey of children and adolescents in the Czech Republic in 2001. Cent Eur J Public Health 12, 126–130, 2004.Search in Google Scholar

Misra S, Vedovato N, Cliff E, De Franco E, Hattersley AT, Ashcroft FM, Oliver NS. Permanent neonatal diabetes: combining sulfonylureas with insulin may be an effective treatment. Diabet Med 35, 1291–1296, 2018.10.1111/dme.1375829896782Search in Google Scholar

Myngheer N, Allegaert K, Hattersley AT, McDonald T, Kramer H, Ashcroft FM, Verhaeghe J, Mathieu C, Casteels K. Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes. Diabetes Care 37, 3333–3335, 2014.10.2337/dc14-1247589480425231897Search in Google Scholar

Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Sovik O, Polak M, Hattersley AT, Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355, 467–477, 2006.10.1056/NEJMoa06175916885550Search in Google Scholar

Stanik J, Gasperikova D, Paskova M, Barak L, Javorkova J, Jancova E, Ciljakova M, Hlava P, Michalek J, Flanagan SE, Pearson E, Hattersley AT, Ellard S, Klimes I. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab 92, 1276–1282, 2007.10.1210/jc.2006-2490761184917213273Search in Google Scholar

Stanik J, Dankovcikova A, Barak L, Skopkova M, Palko M, Divinec J, Klimes I, Gasperikova D. Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation and poor glycaemic control. Diabet Med 35, 386–391, 2018.10.1111/dme.1357529278452Search in Google Scholar

Stanik J, Barak L, Dankovcikova A, Valkovicova T, Skopkova M, Gasperikova D: Diabetes treatment in two pregnant women with permanent neonatal diabetes mellitus due to a KCNJ11 mutation. Diabet Med 2020. Online ahead of print.10.1111/dme.1436332634858Search in Google Scholar

Thurber BW, Carmody D, Tadie EC, Pastore AN, Dickens JT, Wroblewski KE, Naylor RN, Philipson LH, Greeley SA, US Neonatal Diabetes Working Group. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. Diabetologia 58, 1430–1435, 2015,10.1007/s00125-015-3593-9464152325877689Search in Google Scholar